Advanced Glycation End products and benfotiamine

1. Emerging therapy options Protein Glycation and Diabetes Dr. B. K. Iyer

3. The Hypotheses of damage in diabetes

6. Prevalence of diabetic complications in India Ramachandran A,.et al. Prevalence of vascular complications in type 2 diabetes. J Assoc Physicians India. 1999 Dec;47(12):1152-6. Peripheral neuropathy Retinopathy CHD Nephropathy PVD CVD % of patients diagnosed 27.5 23.7 19.7 11.4 4.0 0.9

9. The link in diabetic complications*

13. General Introduction to The “A.G.E. Pathway”

18. The chemistry of glycation in The “A.G.E. Pathway”

19. AGE Formation

20. AGE Formation Amino Acids Sugar Lipid Schiff Base Amadori Product (e.g. HbAlc) Serum and Tissue AGEs Dicarbonyl Intermediates + Polyol Pathway [ox] [ox] glu glu [ox]

23. AGEs in Subjects with & Without Diabetes Beiswenger,PJ et al.Diabetes, 44:824-29,1995 Skin AGEs (Units / mg Collagen

29. Understanding “ A.G.E. role in diabetes”

33. Emerging approach to AGE control

35. Current therapies for diabetes complications

37. AGE inhibitors in diabetes

38. Novel Therapeutic Approaches Transketolase Activators PARP Inhibitors Catalytic Antioxidants

43. AGE inhibitors in diabetes

44. Benfotiamine, Carnosine & Pyridoxine in AGE Protein Glucose Schiff’s base Amadori products AGE + Adapted from Khalilah et al.1999 Benfotiamine Pyridoxine Carnosine Carnosine Benfotiamine AGE breakers after they are formed Carnosine Benfotiamine Pyridoxine

45. Studies with Benfotiamine in Humans

51. Benfotiamine – PPP

62. Studies with L-Carnosine in Humans

66. The product benefits

67. The product benefits

68. Thank you